The prevalence of Hepatitis C is high among people who use drugs and particularly high among people who engage in injection drug use. Despite this, rate of screening and treatment among people who use drugs remains relatively low due to several barriers, including limited access to services. Medical professionals working in substance use treatment spaces, nurses in particular, are well positioned to enhance access and uptake in this population through education, referral, or direct provision.

Learner Objectives

1. Describe the natural history of Hepatitis C (HCV). 
2. Identify health implications for those living with HCV. 
3. Identify harm reduction interventions for preventing or reducing exposure to HCV. 
4. Describe HCV screening recommendations. 
5. Describe HCV treatment and follow-up care.

Presenter

Benjamin Mahoney, DNP, APRN, AGPCNP-BC, CARN-AP, HIVPCP; Rutland Regional Medical Center – West Ridge Center; Rutland, Vermont

Dr. Ben Mahoney is a board-certified nurse practitioner in both adult-gerontology primary care and advanced practice addiction nursing with additional certification in HIV prevention. He currently practices at the West Ridge Center an opioid treatment program in Rutland, Vermont and associated with Rutland Regional Medical Center. In addition to clinical practice, Dr. Mahoney has a clinical research interest in quality improvement in the delivery of care to people who use drugs and a particular interest in the intersectionality of infectious disease and substance use, as well as the expansion of integrated Hepatitis C surveillance, testing, and treatment within substance use disorder treatment settings.

Registration Rates

• ASAN Members: $0, free to members

• Non-Members: $15

• • Not a Member? Click here to join, then sign up for the webinar.

Nursing CE

This event is approved for Nursing CE with the California Board of Nursing.

Cancellation

No refund due to cancellation. All registrants will have access to a video archive if you are unable to attend in person.